Viking Therapeutics up 1% in extended trading after completing enrollment in obesity drug late-stage trial
VKTX Viking Therapeutics Inc
$33.11 -0.96%
차트·분석 보기 → - 1Viking Therapeutics (VKTX) shares rose 1% in Wednesday's extended trading as the company updated progress on its obesity drug program alongside its second-quarter results.
- 2Two large late-stage trials of injectable VK2735 have completed enrollment and are proceeding on schedule, while the late-stage trial of the oral formulation is expected to begin in the fourth quarter of 2026.
- 3As a clinical-stage company with no approved drugs, Viking posted a second-quarter net loss of $128 million and said its $502 million in cash as of the end of June is sufficient to complete the Phase 3 trials.
This 3-line summary is compiled from the report below.
Stocktwits +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다